Posted by Michael Wonder on 02 Apr 2022
Novo Nordisk expands product offerings in Canada for the treatment of haemophilia A in both children and adults, with availability of Esperoct and Zonovate
1 April 2022 - Newly available treatments can help Canadians living with haemophilia A better manage their bleeding episodes
Novo Nordisk announced today that it is extending its product offerings to better support Canadians living with haemophilia A, as both Esperoct (anti-haemophilic factor VIII (recombinant, B domain truncated), PEGylated) and Zonovate (anti-haemophilic factor (recombinant, B domain truncated) are now publicly available through Canadian Blood Services starting 1 April 2022.
Zonovate has been available in Quebec through Hema-Quebec from April 2018.
